Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Interest & Investment Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Interest & Investment Income for 8 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income rose 138.31% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, up 58.75% year-over-year, with the annual reading at $6.2 million for FY2025, 58.75% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.6 million at Whitehawk Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Interest & Investment Income was $2.0 million in Q2 2025, with the low at $1000.0 in Q2 2021.
  • Average Interest & Investment Income over 5 years is $998528.2, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Interest & Investment Income crashed 97.39% in 2021, then skyrocketed 15700.0% in 2022.
  • Over 5 years, Interest & Investment Income stood at $12000.0 in 2021, then soared by 13291.67% to $1.6 million in 2022, then fell by 6.66% to $1.5 million in 2023, then plummeted by 54.93% to $676000.0 in 2024, then skyrocketed by 138.31% to $1.6 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.6 million, $1.8 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.